Skip to main content

Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial

In brief

Twice-yearly azithromycin did not raise antibiotic resistance in Mali trial

In more than 5,000 samples, resistance after twice-yearly azithromycin was about 1 percentage point higher than placebo for both pneumococcus and E. coli, within the trial's prespecified 10-point margin. Quarterly dosing could still cause a modest increase, and the parent trial found no mortality benefit, leaving the balance of benefit and resistance risk uncertain.

Journal
PLoS medicine (Q1)
Published
13 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Jane Juma, Juho Luoma, Awa Traore, Aminata Sangare, Oumou Bouare, Fadima Cheick Haidara, et al.
PMID
43024632
DOI
10.1371/journal.pmed.1005296

Why clinicians should know about it

  • Picked for Pediatrics and Child Health (top studies of the week, 15 November 2026): Randomized infant azithromycin trial sub-study informs antimicrobial resistance
  • Picked for Epidemiology (top studies of the week, 15 November 2026): Cluster trial assesses antimicrobial resistance after mass drug administration

Abstract

BACKGROUND: Mass azithromycin administration has been used to reduce under-five mortality in sub-Saharan Africa, but concerns remain about its potential impact on antimicrobial resistance (AMR). METHODS AND FINDINGS: The Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regiments with Azithromycin (LAKANA) trial was a cluster-randomized, placebo-controlled trial conducted in Mali, enrolling infants aged 1-11 months randomized to placebo, twice-yearly azithromycin, or quarterly azithromycin for 2 years. The trial did not find any mortality benefit amongst treated children. The current analysis is a sub-study of the parent trial examining AMR outcomes. Repeated cross-sectional nasopharyngeal and rectal swabs were collected from children aged 4-14-months in villages randomized to placebo, twice-yearly or quarterly azithromycin, and from untreated contacts aged 49-59-months at baseline, 12-, 24-, and 36-months post-village enrollment across 59 LAKANA trial villages. Phenotypic resistance to macrolide and nonmacrolide antibiotics was assessed in Streptococcus pneumoniae (S. pneumoniae) and Escherichia coli (E. coli) isolates using disk diffusion or E-tests. The primary noninferiority analysis evaluated macrolide resistance prevalence at 36-months among younger children and at 24-months among older contacts, with predefined margin of +10 percentage points. A total of 5,025 nasopharyngeal and 5,021 rectal samples were analyzed. At baseline, among 4-14-month-old children, macrolide resistance in S. pneumoniae was 16.6%, 15.5%, and 11.1% in the placebo, twice-yearly and quarterly azithromycin groups, respectively, and 5.0%, 5.0%, and 0.0% in E. coli. At 36-months, corresponding prevalences were 13.4%, 14.5%, and 17.2% for S. pneumoniae, and 5.1%, 6.4%, and 9.1% for E. coli. The difference between placebo and twice-yearly groups was 1.0% (95% CI [-4.7, 6.8]) for S. pneumoniae and 1.3% (95% CI [-2.4, 4.9]) for E. coli; corresponding differences for quarterly azithromycin group was 3.8% (95% CI [-3.3, 10.9]) for S. pneumoniae and 4.0% (95% CI [-0.7, 8.7]) for E. coli. Among untreated older children, there were no marked inter-group differences in macrolide resistance either at baseline or at 24-months. The study may not have been large enough to detect a small increase in macrolide resistance in S. pneumoniae among young children in villages that received quarterly azithromycin. CONCLUSIONS: Twice-yearly azithromycin administration to 1-11-month-old infants for 2 years in Mali did not increase macrolide resistance in treated children or untreated contacts and met the predefined noninferiority margin in tested isolates. Quarterly administration, however, cannot exclude a modest dose-dependent increase of macrolide resistance in S. pneumoniae and E. coli.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.